title: Is Cdc25 a druggable target?
abstract: Proper control of cell cycle progression requires the functionality of a small family of activating phosphatases termed Cdc25, which have been implicated in cancer and Alzheimer's disease. These protein tyrosine phosphatases are therefore recognized as attractive molecular targets for small molecules. We review the rationale, approaches, progress and challenges for developing small molecule inhibitors of the Cdc25 family. A number of potential chemical probes are discussed and their characteristics are summarized.
authors.affiliation: Department of Pharmacology and Chemical Biology, Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA. lazo@pitt.edu
authors.forename: John S
authors.initials: JS
authors.lastname: Lazo
authors.forename: Peter
authors.initials: P
authors.lastname: Wipf
mesh_terms: D000818:Animals; D002453:Cell Cycle; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D020687:cdc25 Phosphatases / Q000037:antagonists & inhibitors*
chemical_list: D004791:Enzyme Inhibitors; D020687:cdc25 Phosphatases